Oral Micronized Progesterone for Perimenopause: Evidence Summary
A clinical evidence summary on using oral micronized progesterone (Prometrium) off-label for perimenopause symptoms including hot flashes, sleep disruption, and irregular bleeding.
Rezdiffra Trial Design: MAESTRO-NASH Results & Monitoring
MAESTRO-NASH: 26% on 100mg resmetirom achieved NASH resolution vs 10% placebo at 52 weeks. See dosing, monitoring labs, and imaging schedule for F2-F3 fibrosis.
Saxenda for PCOS: Off-Label Evidence Summary for Liraglutide 3 mg
A clinical evidence summary of Saxenda (liraglutide 3 mg) used off-label for polycystic ovary syndrome (PCOS), covering trial data, hormonal outcomes, weight effects, and prescribing considerations.
TB-500 for Muscle Recovery: Evidence Summary
A clinical review of TB-500 (thymosin beta-4 active fragment) for muscle recovery, including preclinical evidence, off-label status, dosing protocols, and safety considerations.
Testosterone Cypionate for Frailty Syndrome: Monitoring Requirements and Off-Label Evidence
A guide to monitoring testosterone cypionate when used off-label for frailty syndrome, including lab schedules, safety signals, and evidence-based protocols.
Wegovy for Alcohol Use Disorder: What the Evidence Actually Shows
Semaglutide 2.4 mg (Wegovy) is not FDA-approved for alcohol use disorder, but emerging preclinical and observational data suggest GLP-1 receptor agonists may reduce alcohol intake. Here is what clinicians and patients need to know.
Oral Micronized Progesterone in Adults 65+: Geriatric Safety Guide
Evidence-based safety review of oral micronized progesterone (Prometrium) in geriatric patients aged 65 and older, covering dosing, risks, monitoring, drug interactions, and deprescribing.
Does State Medicaid Cover Oral Micronized Progesterone (Prometrium)?
State Medicaid coverage for oral micronized progesterone varies widely. Learn formulary tiers, prior authorization rules, step therapy requirements, and how to appeal a denial.
Oral Minoxidil Dosing for Adults (30 to 49): Evidence-Based Guide
How low-dose oral minoxidil is dosed for hair loss in adults aged 30 to 49, including starting doses, titration patterns, monitoring, and the boundaries between label guidance and individualized prescribing.
Oral Minoxidil Overdose: Recognition, Management, and What to Do After an Accidental Extra Dose
If you took too much oral minoxidil, contact Poison Control now. Learn what details matter, which symptoms need 911, and why no universal home dose cutoff is responsible.
Oral Minoxidil Storage, Stability & Shelf Life: What Patients and Pharmacists Need to Know
Evidence-based guide to oral minoxidil storage conditions, chemical stability data, compounded formulation shelf life, and practical handling tips for low-dose minoxidil tablets.
Does TRICARE Cover Oral Minoxidil? Formulary, Prior Auth, and Appeal Steps
Find out whether TRICARE covers oral minoxidil for hair loss, what formulary tier it falls on, prior authorization requirements, step therapy rules, and how to appeal a denial.
Ozempic Manufacturing, Supply, and Shortage History
A detailed look at how Ozempic (semaglutide) is manufactured, what caused its prolonged shortage, and what the current supply outlook means for patients with type 2 diabetes.
How to Self-Inject Ozempic: Step-by-Step Semaglutide Injection Technique
A guide to Ozempic (semaglutide) self-injection technique covering pen preparation, site selection, needle handling, dose titration, and troubleshooting common errors.
What Peptides Do Women Use for Anti-Aging?
Evidence-based guide to the peptides women use for anti-aging, including GHK-Cu, collagen peptides, CJC-1295/ipamorelin, BPC-157, and epithalon. Doses, evidence, and safety reviewed.
Prometrium Monitoring Schedule: Labs, Exams, and Follow-Up Timelines
A monitoring schedule for Prometrium (micronized progesterone), covering baseline labs, follow-up bloodwork, endometrial surveillance, and long-term exam timelines.
PT-141 (Bremelanotide) Dosing in Hepatic Impairment
Evidence-based guide to bremelanotide (Vyleesi) dosing adjustments in patients with hepatic impairment, including pharmacokinetic data, clinical recommendations, and monitoring protocols.
Rapamycin (Sirolimus): History and Development From Easter Island to Modern Medicine
The complete history of rapamycin (sirolimus), from its 1972 discovery in Easter Island soil to FDA approval and current longevity research. Mechanism of action, key trials, and clinical development timeline.
Rapamycin (Sirolimus) Dosing for Older Adults (50 to 64): What the Evidence Supports
Evidence-based guide to rapamycin (sirolimus) dosing in older adults aged 50 to 64, covering off-label longevity protocols, FDA-approved transplant doses, safety monitoring, and age-specific considerations.
Amlodipine FDA Approval History: Timeline, Label Changes, and Post-Market Safety
A complete timeline of amlodipine's FDA approval, label updates, generic entry, and post-market safety data from 1987 NDA filing through 2026.
BPC-157 Label Updates 2020 to 2026: FDA Actions, Compounding Rules, and What Changed
A full regulatory timeline of BPC-157 from 2020 through 2026, covering FDA compounding decisions, safety notices, and why this peptide has no approved label.
Vyleesi EMA vs FDA Approach: How Bremelanotide Regulation Differs Across Agencies
A clinical comparison of how the FDA and EMA evaluated Vyleesi (bremelanotide) for hypoactive sexual desire disorder, including approval timelines, label restrictions, safety signals, and post-market requirements.
Prolia (Denosumab) FDA Approval History
A detailed regulatory timeline of denosumab (Prolia/Xgeva) from initial FDA approval through post-market safety updates, label expansions, and biosimilar developments.
Trulicity (Dulaglutide) FAERS Safety Signals: What Post-Market Surveillance Shows
A detailed review of dulaglutide (Trulicity) safety signals reported through the FDA Adverse Event Reporting System (FAERS), including gastrointestinal events, pancreatitis, thyroid concerns, and cardiovascular outcomes from the REWIND trial.
Enclomiphene Citrate FAERS Safety Signals: What the FDA Adverse Event Data Actually Shows
A clinician-focused review of enclomiphene citrate safety signals in the FDA Adverse Event Reporting System (FAERS), regulatory status, compounding considerations, and post-market surveillance data.
Oral Estradiol Legal and Patent Challenges: FDA History, Label Updates, and Safety Disputes
A clinical review of oral estradiol's regulatory history, patent field, generic entry, FDA label evolution, and ongoing legal and safety controversies tied to the WHI trial and post-market surveillance.
Estradiol Patch: EMA vs FDA Regulatory Approaches Compared
A clinical comparison of how the FDA and EMA regulate estradiol transdermal patches, including approval history, labeling differences, post-market surveillance, and what these divergences mean for prescribers and patients.
Repatha (Evolocumab): Legal and Patent Challenges, FDA History, and Regulatory Field
A clinical review of Repatha's FDA approval history, patent disputes with Sanofi/Regeneron, label updates, post-market safety surveillance, and the regulatory path that shaped PCSK9 inhibitor access.
Finasteride Compounding Legal Status: FDA Approval, Label Details, and Regulatory History
A clinical review of finasteride's FDA approval history, current compounding legal status, official label warnings, and post-market safety surveillance data.
Addyi (Flibanserin) Legal and Patent Challenges: FDA History, REMS, and Generic Access
A clinical review of Addyi's FDA approval history, patent disputes, REMS modifications, and the legal battles that shaped flibanserin access for women with HSDD.
Ipamorelin Label Updates 2020 to 2026: FDA Status, Compounding Rules, and Safety Signals
A clinical review of ipamorelin's regulatory trajectory from 2020 through 2026, covering FDA compounding oversight, label-equivalent guidance changes, post-market safety data, and what prescribers need to know.
Accutane Recall: Why Roche Pulled It in 2009
Accutane was withdrawn in 2009 after IBD lawsuits; generic isotretinoin still sold under the iPLEDGE REMS program. Full legal and patent timeline inside.
Jatenzo Compounding Legal Status: FDA Approval, Label Details, and Regulatory Outlook
Complete regulatory breakdown of Jatenzo (oral testosterone undecanoate), including its FDA approval history, prescribing label specifics, compounding legal status under federal law, and what patients and clinicians need to know about access.
MK-677 (Ibutamoren) FDA Approval History
MK-677 (ibutamoren) has never received FDA approval. Review the full regulatory timeline, clinical trial record, FDA enforcement actions, and safety data for this investigational growth hormone secretagogue.
Mounjaro Global Regulatory Status: FDA Approval, EMA Authorization, and Worldwide Label Updates
A complete guide to Mounjaro (tirzepatide) regulatory approvals worldwide, including FDA labeling, EMA authorization, post-market safety surveillance, and ongoing label expansions.
NMN and NR: EMA vs FDA Regulatory Approach
How the FDA and EMA classify nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), including supplement status, novel food authorization, clinical evidence, and what consumers need to know.
Oral Micronized Progesterone FDA Approval History
Complete FDA approval history of oral micronized progesterone (Prometrium), including regulatory milestones, label updates, post-market safety data, and clinical trial evidence from PEPI through current guidelines.
Oral Micronized Progesterone Label Updates 2020 to 2026
A comprehensive review of FDA label changes for oral micronized progesterone (Prometrium) from 2020 through 2026, including safety updates, boxed warning revisions, and clinical implications for prescribers.
Oral Micronized Progesterone FAERS Safety Signals: What FDA Post-Market Data Actually Show
A clinical breakdown of oral micronized progesterone (Prometrium) FAERS safety signals, FDA post-market surveillance findings, label warnings, and what the adverse-event data mean for patients and prescribers.
Ozempic Global Regulatory Status: FDA Approval, Label Updates, and International Oversight
A clinical review of Ozempic (semaglutide) regulatory approvals worldwide, including FDA labeling, EMA authorization, post-market safety surveillance, and ongoing label expansions.
Actos (Pioglitazone) Label Updates 2020 to 2026: FDA Safety Changes, Warnings, and Clinical Context
A review of pioglitazone (Actos) label content and FDA safety communications relevant to prescribing decisions from 2020 through 2026, covering bladder cancer language, heart failure warnings, bone fracture risk, and off-label NASH/MASH use, with explicit flags where source figures require independent verification.
PT-141 (Bremelanotide) Compounding Legal Status: FDA Approval, Label Details, and Safety
Current regulatory and compounding status of PT-141 (bremelanotide), including FDA approval history, Vyleesi labeling, 503A/503B compounding rules, and post-market safety data.
PT-141 (Bremelanotide): Legal and Patent Challenges
A clinical review of bremelanotide (Vyleesi/PT-141) legal history, patent disputes, FDA regulatory pathway, label requirements, and ongoing post-market safety obligations.
Evenity (Romosozumab) Compounding Legal Status: FDA Approval, Label, and Regulatory Overview
Complete regulatory breakdown of Evenity (romosozumab), including FDA approval history, boxed warning details, compounding legality, EMA status, and post-market safety surveillance data.
Crestor Label Updates 2020-2026: What Changed
FDA revised the Crestor (rosuvastatin) label six times since 2020, adding interaction warnings, new renal dosing limits, and updated myopathy risk language.
Rybelsus Release Date: FDA Approval History and Label Changes
Rybelsus was FDA approved September 20, 2019, the first oral GLP-1 tablet. See PIONEER trial data, dosing, and safety label updates since approval.
Saxenda Legal & Patent Challenges: FDA History, Label Updates, and Litigation
A clinical review of Saxenda (liraglutide 3 mg) legal and patent challenges, including FDA approval history, post-market safety signals, label changes, and Novo Nordisk patent litigation.
Sermorelin: EMA vs FDA Regulatory Approach
A detailed comparison of how the FDA and EMA have handled sermorelin acetate, from its original 1997 approval through withdrawal and current compounding status.
Sermorelin FDA Approval History: Timeline, Label Changes, and Current Regulatory Status
A complete regulatory history of sermorelin acetate, from its 1997 FDA approval through voluntary market withdrawal and current 503A compounding status, with clinical trial data and safety context.
Sermorelin Label Updates 2020 to 2026: FDA Status, Compounding Rules, and Safety Data
A comprehensive review of sermorelin acetate label changes, FDA regulatory actions, compounding pharmacy status, and post-market safety data from 2020 through 2026.
TB-500 Compounding Legal Status: FDA Approval, Safety, and What Patients Need to Know
TB-500 (thymosin beta-4 active fragment) has no FDA approval. Learn its current compounding legal status under 503A pharmacy rules, safety data, labeling gaps, and what the regulatory field means for patients.
TB-500 Pipeline and Next-Gen: FDA Status, Clinical Trials, and What Comes After Thymosin Beta-4
Where TB-500 (thymosin beta-4 fragment) stands in the FDA pipeline, what clinical trials exist, and what next-generation derivatives may replace it. prepared by the HealthRX.com Editorial Team.
Topical Minoxidil FDA Approval History
A complete regulatory timeline of topical minoxidil from its original cardiovascular use through OTC reclassification, label expansions, and ongoing post-market safety surveillance.
Topical Minoxidil Label Updates 2020 to 2026: FDA Changes, Safety Signals, and What They Mean
The FDA topical minoxidil Drug Facts label covers twice-daily use, stop-use for chest pain or resting heart rate above 100 bpm, and facial hair growth.
Vaginal Estradiol: EMA vs FDA Regulatory Approach
How the FDA and EMA differ on vaginal estradiol approval, labeling, safety monitoring, and prescribing guidance for genitourinary syndrome of menopause.
Wegovy FDA Approval History: Timeline, Label Changes, and Safety Updates
The Wegovy FDA label covers three indications: adult weight management (BMI ≥30 or ≥27 with a comorbidity), ages 12+, and cardiovascular risk reduction.
Zepbound EMA vs FDA Approach: How Tirzepatide Regulation Differs Across Agencies
A detailed comparison of how the FDA and EMA regulate Zepbound (tirzepatide) for weight management, including approval timelines, label differences, post-market surveillance, and safety monitoring frameworks.
Rezdiffra (Resmetirom) Missed-Dose Protocol: What to Do If You Skip a Dose
Evidence-based missed-dose protocol for Rezdiffra (resmetirom), including timing rules, pharmacokinetic rationale, and clinical guidance for patients with MASH.
Rezdiffra (Resmetirom) Regulatory Status: US, EU, Canada, UK Approval Tracker
Rezdiffra is not approved in Canada as of mid-2026: Madrigal filed a New Drug Submission with Health Canada, but no Notice of Compliance has been issued.
CJC-1295 Satisfaction Trends Over Time: What Real Users Report
Analysis of CJC-1295 user satisfaction trends from Reddit, forums, and clinical data. Learn what real users experience at 4, 8, and 12+ weeks and how results compare to trial benchmarks.